Safety of Anlotinib Capsules Combined with PD-1 Inhibitor Camrelizumab in the Third-Line Treatment of Advanced Non-Small-Cell Lung Cancer and Their Effect on Serum Tumor Markers

Figure 2

Comparison of CFS scores after treatment (mean ± SD). Note: the abscissa was STG and CTG, and the ordinate was the CFS score (points). The average CFS scores after treatment in the STG and CTG were 69.75 ± 3.38 and 55.16 ± 7.09. indicated an obvious difference in the average CFS scores after treatment between the two groups (t = 12.322,  < 0.001).